Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN36658311
ISRCTN36658311
Completed
Not Applicable

A multicentre study of the safety and efficacy of N-acetylcysteine in the treatment of acute liver failure in paediatric patients not caused by acetaminophe

King's College Hospital NHS Foundation Trust (UK)0 sites28 target enrollmentMay 12, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsTopic: Medicines for Children Research NetworkSubtopic: All DiagnosesDisease: All DiseasesDigestive SystemAcute liver failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Topic: Medicines for Children Research Network
Sponsor
King's College Hospital NHS Foundation Trust (UK)
Enrollment
28
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 12, 2010
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional

Investigators

Sponsor
King's College Hospital NHS Foundation Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • •Enrolment in PALF registry:
  • •1\. Evidence of acute liver injury
  • •2\. International normalised ratio (INR) greater than or equal to 1\.5 or prothrombin time (PT) greater than or equal to 15 with encephalopathy, or INR greater than or equal to 2\.0 or PT greater than or equal to 20 with or without encephalopathy
  • •3\. Aged less than 18 years, either sex
  • •4\. Informed consent, obtained from the patient or parent

Exclusion Criteria

  • •1\. Acute paracetomol toxicity
  • •2\. Patient on N\-acetylcysteine or received N\-acetylcysteine during the course of this illness
  • •3\. Pregnancy
  • •4\. Known malignancy
  • •5\. Patient is on a liver support device
  • •7\. Signs of cerebral herniation
  • •8\. Intractable hypotension

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A multi-center study of the safety and efficacy of the percutaneous transvenous mitral annuloplasty system to reduce mitral valve regurgitation in patients with heart failure.mitral regurgitationmitral valve leakage10046973
NL-OMON33252Viacor Inc.14
Completed
Not Applicable
A Multicenter study of the safety and efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in patients with hypophosphatasia (HPP)
JPRN-UMIN000014816HPP study group20
Active, not recruiting
Not Applicable
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)
EUCTR2006-006522-25-BECSL Behring AG28
Active, not recruiting
Not Applicable
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)Patients with PID diseases as Common Variable Immunodeficiency (CVID) or X-linked agammaglobulinemia ( XLA), age 1 to 70 yearsMedDRA version: 8.1Level: LLTClassification code 10010112Term: Common variable immunodeficiency
EUCTR2006-006522-25-DECSL Behring AG28
Active, not recruiting
Phase 1
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)Patients with PID diseases as Common Variable Immunodeficiency (CVID) or X-linked agammaglobulinemia ( XLA), age 1 to 70 yearsMedDRA version: 8.1Level: LLTClassification code 10010112Term: Common variable immunodeficiency
EUCTR2006-006522-25-GRCSL Behring AG18